Related references
Note: Only part of the references are listed.Dry Eye Disease An Immune-Mediated Ocular Surface Disorder
William Stevenson et al.
ARCHIVES OF OPHTHALMOLOGY (2012)
Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Shiao Hui (Melissa) Liew et al.
OPHTHALMOLOGY (2012)
Immunomodulatory Effect of the Topical Ophthalmic Janus Kinase Inhibitor Tofacitinib (CP-690,550) in Patients with Dry Eye Disease
Jing-Feng Huang et al.
OPHTHALMOLOGY (2012)
PDE4 Inhibition Suppresses IL-17-Associated Immunity in Dry Eye Disease
Zahra Sadrai et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Interferon-γ-secreting NK cells promote induction of dry eye disease
Yihe Chen et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Treating inflammation with the Janus Kinase inhibitor CP-690,550
Lalitha Vijayakrishnan et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Inflammatory Corneal Neovascularization: Etiopathogenesis
John L. Clements et al.
SEMINARS IN OPHTHALMOLOGY (2011)
Effect of Topical Azithromycin on Corneal Innate Immune Responses
Zahra Sadrai et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
The Jak Inhibitor CP-690,550 Preserves the Function of CD4+CD25brightFoxP3+Regulatory T Cells and Inhibits Effector T Cells
V. D. K. D. Sewgobind et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
Debra M. Meyer et al.
JOURNAL OF INFLAMMATION-LONDON (2010)
Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients
S. Busque et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Amelioration of Murine Dry Eye Disease by Topical Antagonist to Chemokine Receptor 2
Sunali Goyal et al.
ARCHIVES OF OPHTHALMOLOGY (2009)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G. Boy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
IL-17 disrupts corneal barrier following desiccating stress
C. S. De Paiva et al.
MUCOSAL IMMUNOLOGY (2009)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
The controlled-environment chamber: A new mouse model of dry eye
S Barabino et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation
P Hamrah et al.
ARCHIVES OF OPHTHALMOLOGY (2003)
Signaling through the JAK/STAT pathway, recent advances and future challenges
T Kisseleva et al.
GENE (2002)
Locally administered ocular corticosteroids - Benefits and risks
CNJ McGhee et al.
DRUG SAFETY (2002)
Share Paper
